Company intelligence / Profile preview

Genset

Paris, France

Ownership: Private
Development stage: Other

Overview

Genset was a pioneer in human genome research and pharmacogenomics, launching large-scale genomic mapping and SNP analysis programs. It initiated the first pharmacogenomics research program globally in collaboration with Abbott Laboratories. Genset was the European flagship in genomics, becoming the second-largest biotech company in Europe by 1999. The company shifted to drug development after 2000 but was ultimately acquired by Serono in 2002 due to strategic challenges.

Therapeutic areas: NeurologyMetabolic DisordersRare Diseases
Modalities: GenomicsPharmacogenomicsSmall molecule
Industry: Biotech

Partnerships

Abbott Laboratories (Pharmacogenomics research)

Beyond the preview

Go deeper on Genset.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genset.

Explore the full profile